skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

63 Total results for product and free and sample content found

In Vivo Outlook 2021 Report

16 Jun 2022

In Vivo Outlook 2021 Report

The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information. 

Topic deal-trends biopharmaceutical business-strategies

Clinical Trial Webinar Series

16 Apr 2021

Clinical Trial Webinar Series

Learn about the latest trends affecting biopharma R&D including, study diversity & transparency, predictive feasibility and more...

Topic Coronavirus clinical-trials biopharmaceutical

2021 Scrip Pharma Trends

25 Feb 2021

For Scrip’s annual preview our journalists asked over 200 industry executives and experts for their predictions of the major trends for 2021. From the pandemic, to AI, therapeutics, and the new US leadership, here’s what to watch out for – in a year with so much at stake.

Quick Listen: Scrip’s Five Must-Know Things

22 Feb 2021

SC2008_FiveMustKnowThings_1200_Final

A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.

Topic biopharmaceutical

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

By Penelope MacRae 27 Nov 2020

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

Topic fda diabetes biopharmaceutical

A Positive Outlook For Deals, With Election Year Caveats

By Jessica Merrill 27 Nov 2020

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.

Topic BioPharmaceutical

2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts

27 Nov 2020

2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts

See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.  

Topic drug-development-landscape biopharmaceutical business-strategies

Pfizer And BioNTech Claim COVID19 Vaccine Success

By Andrew McConaghie 17 Nov 2020

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Topic Coronavirus biopharmaceutical

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: